MD MBA - Clearside Biomedical Chief AdvisorRetina
| CLSD Stock | USD 1.05 0.02 1.87% |
Executive
MD MBA is Chief AdvisorRetina of Clearside Biomedical
| Age | 59 |
| Address | 900 North Point Parkway, Alpharetta, GA, United States, 30005 |
| Phone | 678 270 3631 |
| Web | https://clearsidebio.com |
Clearside Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.4405) % which means that it has lost $0.4405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.1002) %, meaning that it created substantial loss on money invested by shareholders. Clearside Biomedical's management efficiency ratios could be used to measure how well Clearside Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.14, whereas Return On Tangible Assets are forecasted to decline to (1.00). At present, Clearside Biomedical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 35.9 M, whereas Other Current Assets are forecasted to decline to about 670.7 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Leonard MD | C4 Therapeutics | 62 | |
| Donald Notman | Ocular Therapeutix | 57 | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Kendra Adams | C4 Therapeutics | N/A | |
| Edward Horst | Sensei Biotherapeutics | 50 | |
| Kevin Shaw | NextCure | 49 | |
| Christopher Nasveschuk | C4 Therapeutics | N/A | |
| Charles Lin | Kronos Bio | 39 | |
| Allison JD | Kronos Bio | 41 | |
| Nkengyal Barber | ESSA Pharma | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| John Bishop | Lyra Therapeutics | 62 | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| William Slattery | Ocular Therapeutix | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Chandra MS | Erasca Inc | 53 | |
| Michael Varney | Erasca Inc | 66 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| MS MBA | Sensei Biotherapeutics | 46 | |
| Tracy Smith | Ocular Therapeutix | N/A | |
Management Performance
| Return On Equity | -13.1 | ||||
| Return On Asset | -0.44 |
Clearside Biomedical Leadership Team
Elected by the shareholders, the Clearside Biomedical's board of directors comprises two types of representatives: Clearside Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clearside. The board's role is to monitor Clearside Biomedical's management team and ensure that shareholders' interests are well served. Clearside Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clearside Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief AdvisorRetina | ||
| Jenny Kobin, Head Relations | ||
| FRCOphth FRCS, Chief Officer | ||
| Leslie Zacks, Chief Compliance Officer, General Counsel | ||
| Charles Deignan, Chief Officer | ||
| Susan Coultas, Chief Officer | ||
| Rafael Andino, Vice President - Engineering & Manufacturing | ||
| JD PharmD, CEO Pres | ||
| Rick McElheny, Senior Management |
Clearside Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clearside Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.1 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (84.33) % | ||||
| Current Valuation | 56.83 M | ||||
| Shares Outstanding | 75.84 M | ||||
| Shares Owned By Insiders | 7.38 % | ||||
| Shares Owned By Institutions | 23.16 % | ||||
| Number Of Shares Shorted | 1.52 M | ||||
| Price To Earning | 130.00 X | ||||
| Price To Book | 3.93 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.91) | Return On Assets (0.44) | Return On Equity (13.10) |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.